JP2024535930A5 - - Google Patents
Info
- Publication number
- JP2024535930A5 JP2024535930A5 JP2024519706A JP2024519706A JP2024535930A5 JP 2024535930 A5 JP2024535930 A5 JP 2024535930A5 JP 2024519706 A JP2024519706 A JP 2024519706A JP 2024519706 A JP2024519706 A JP 2024519706A JP 2024535930 A5 JP2024535930 A5 JP 2024535930A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- variable region
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163249728P | 2021-09-29 | 2021-09-29 | |
| US63/249,728 | 2021-09-29 | ||
| US202263326572P | 2022-04-01 | 2022-04-01 | |
| US63/326,572 | 2022-04-01 | ||
| PCT/CA2022/051437 WO2023049999A1 (en) | 2021-09-29 | 2022-09-28 | Binding agents targeting trop2-expressing tumor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535930A JP2024535930A (ja) | 2024-10-02 |
| JP2024535930A5 true JP2024535930A5 (https=) | 2025-10-08 |
Family
ID=85780298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519706A Pending JP2024535930A (ja) | 2021-09-29 | 2022-09-28 | Ｔｒｏｐ２発現腫瘍細胞を標的化する結合剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20240360242A1 (https=) |
| EP (1) | EP4408893A4 (https=) |
| JP (1) | JP2024535930A (https=) |
| KR (1) | KR20240082383A (https=) |
| AU (1) | AU2022357634A1 (https=) |
| CA (1) | CA3231574A1 (https=) |
| IL (1) | IL311673A (https=) |
| MX (1) | MX2024003779A (https=) |
| TW (1) | TW202330605A (https=) |
| WO (1) | WO2023049999A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4408893A4 (en) | 2021-09-29 | 2026-02-18 | Kisoji Biotechnology Inc | Binding agents targeting tumor cells expressing too much 2 |
| CN121419995A (zh) * | 2023-04-04 | 2026-01-27 | 加拿大商木曾路生物科技公司 | 靶向表达trop2的肿瘤细胞的结合剂 |
| WO2024051383A1 (zh) * | 2023-07-28 | 2024-03-14 | 上海洛启生物医药技术有限公司 | 抗Trop2抗体、包含所述抗体的缀合物及其应用 |
| WO2026059880A1 (en) * | 2024-09-12 | 2026-03-19 | Modernatx, Inc. | Trop2 binding molecules, nucleic acids encoding same, and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201500220A1 (ru) | 2010-05-17 | 2015-10-30 | Ливтех, Инк. | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo |
| WO2011155579A1 (ja) | 2010-06-10 | 2011-12-15 | 北海道公立大学法人札幌医科大学 | 抗Ｔｒｏｐ－２抗体 |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| CN116199790A (zh) * | 2015-02-10 | 2023-06-02 | 米纳瓦生物技术公司 | 人源化抗MUCl*抗体 |
| EP3600283A4 (en) * | 2017-03-27 | 2020-12-16 | Immunomedics, Inc. | TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR |
| GB201811368D0 (en) * | 2018-07-11 | 2018-08-29 | Ucb Biopharma Sprl | Antibody |
| CN112646038B (zh) * | 2019-10-11 | 2025-06-03 | 迈威(上海)生物科技股份有限公司 | 抗人Trop-2抗体及其应用 |
| EP4077374A4 (en) | 2019-12-20 | 2023-12-27 | Kisoji Biotechnology Inc. | POLYPEPTIDES, PROTEIN COMPLEXES AND METHODS FOR PRODUCING THE SAME |
| CN113527496B (zh) * | 2020-04-16 | 2022-03-04 | 上海洛启生物医药技术有限公司 | 抗Trop2纳米抗体及其应用 |
| CN112321715B (zh) * | 2020-11-03 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 抗trop2纳米抗体及其制备方法和应用 |
| CN114685669A (zh) | 2020-12-30 | 2022-07-01 | 和铂医药(苏州)有限公司 | 结合trop2的抗体及其用途 |
| EP4408893A4 (en) | 2021-09-29 | 2026-02-18 | Kisoji Biotechnology Inc | Binding agents targeting tumor cells expressing too much 2 |
-
2022
- 2022-09-28 EP EP22874016.3A patent/EP4408893A4/en active Pending
- 2022-09-28 JP JP2024519706A patent/JP2024535930A/ja active Pending
- 2022-09-28 MX MX2024003779A patent/MX2024003779A/es unknown
- 2022-09-28 IL IL311673A patent/IL311673A/en unknown
- 2022-09-28 CA CA3231574A patent/CA3231574A1/en active Pending
- 2022-09-28 KR KR1020247014071A patent/KR20240082383A/ko active Pending
- 2022-09-28 WO PCT/CA2022/051437 patent/WO2023049999A1/en not_active Ceased
- 2022-09-28 AU AU2022357634A patent/AU2022357634A1/en active Pending
- 2022-09-29 TW TW111137049A patent/TW202330605A/zh unknown
-
2024
- 2024-03-28 US US18/620,397 patent/US20240360242A1/en active Pending
- 2024-05-14 US US18/664,070 patent/US12338295B2/en active Active
- 2024-05-14 US US18/664,091 patent/US12275799B2/en active Active
- 2024-05-14 US US18/664,078 patent/US12371508B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024535930A5 (https=) | ||
| JP2025011178A5 (https=) | ||
| JP2023509323A5 (https=) | ||
| HRP20240626T1 (hr) | Bispecifična antitijela protiv ceacam5 i cd3 | |
| JP2020501531A5 (https=) | ||
| US20100092455A1 (en) | Novel anti-proliferation antibodies | |
| JP2017500028A5 (https=) | ||
| EP4155319A1 (en) | 4-1bb binding protein and application thereof | |
| JP2025092589A5 (https=) | ||
| EP4154910A1 (en) | Binding protein having h2l2 and hcab structures | |
| JP2022512642A5 (https=) | ||
| JP2024016024A5 (https=) | ||
| JP2021512107A5 (https=) | ||
| US20230051266A1 (en) | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof | |
| US9717715B2 (en) | Method of combination therapy using an anti-C-Met antibody | |
| JP2025513745A5 (https=) | ||
| JP2024533457A5 (https=) | ||
| JP2024536383A5 (https=) | ||
| JP2024522075A5 (https=) | ||
| AU2019306113B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| CN119176876A (zh) | 抗b7-h4抗体及其应用 | |
| JP2024540062A5 (https=) | ||
| WO2022057910A1 (en) | Combination therapies targeting c5ar and pd-1/pd-l1 pathways | |
| JP2024522234A5 (https=) | ||
| US20220265821A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas |